Varicella-zoster virus (VZV) infections are widely distributed in the general population. The lifetime risk of herpes zoster is estimated to be 10-20 %, increasing with age (1-4). Since herpes zoster ophthalmicus (HZO) accounts for 20 % of all locations of shingles, the lifetime risk of HZO is about 1-2 %. The management of ocular complications of VZV infection is now well codified, but sequellae still can occur, despite an armamentarium effective in limiting viral replication and its immune consequences.
of VZV is a rare event. it occurs in the sensory ganglia of the clinically affected dermatomes. HZO corresponds to a reactivation in the trigeminal ganglia. During reactivation, a new phase of viremia can lead to atypical presentations with multifocal visceral complications, 4, 9 or conversely without cutaneous signs (zoster sine herpete), [10] [11] [12] among which anterior uveitis or necrotizing retinitis. [13] [14] [15] Epidemiology in countries where large-scale vaccination is not recommended, chickenpox mainly affects people under 20 years with an annual incidence estimated between 1.3 and 3.4 per 1000 people. For shingles, the annual incidence increases with age. it ranges from around 1 per 1000 people among persons 20 to 30 years to 11 per 100 in people over 70 years. 3, 16 Age is the major risk factor for shingles. The incidence is growing rapidly after 60 years 1 and it reaches 50 %in patients over 85 years who had
Pathophysiology: The three Phases of Varicella Zoster Virus Infection The Primary Infection
This mostly occurs during childhood and early years of adult life.
Varicella zoster virus is a highly contagious infection and spread both by respiratory droplets and direct contact. Primary infection begins with oropharyngeal infection followed by viremia, which leads to the diffusion into the skin (chickenpox) and the nervous system where VZV may ultimately establish a latent infection. Extra-cutaneous manifestations are infrequent and include neurological, pulmonary, hepatic and ocular complications. They are rare and proteiform, including conjunctivitis, episcleritis, dendritic keratitis and/or stromal non-necrotic, sclerokeratitis, anterior uveitis, or retinitis. 4 However, most primary infections remain asymptomatic. Primary varicella infection during pregnancy can rarely result in intrauterine infection of the fetus, presenting as congenital varicella syndrome with micromelia, microcephaly, skin scarring and dysautonomic syndrome. 5 Recently, the varicella vaccine has significantly modified the epidemiological data in countries where vaccination is usual. in US, the number of severe cases of varicella (i.e. with neurologic or pulmonary lesions) was reduced by 90 % since the vaccine was approved by the US food and drug administration (FDA) in 1995. 4 
Latency and Clinical Quiescence
Varicella zoster virus has the capacity to become latent in the nervous system. Studies based on molecular biology techniques have shown that almost all people over 60 years are latently infected with Varicella zoster virus. 6 Although numerous neurological tissues have been described as not been previously affected. 8, 17 immunosuppresion is a risk factor of recurrent herpes zoster, which incidence rises from 2-4 % in the general population to 25 % among severely immunocompromised patients. 4, 18 The lifetime risk of herpes zoster is estimated to be 10-20 %. 2 Since HZO accounts for 20 % of all locations of shingles, the risk of HZO is comprised between about 1 and 4 % over a lifetime.
Presentation

General and Dermatologic Signs
The prodromal phase of HZO usually includes an influenzalike illness with fatigue, malaise, and low-grade fever prior to the development of unilateral rash over the forehead, upper eyelid, and nose (the first division of trigeminal nerve dermatome.
Dermatomal pain can also precede the eruption. Subsequently, erythematous macules appear and progress to form clusters of papules and vesicles.
These lesions then evolve into pustules, which quickly lyse and crust over.
New blisters continue to appear over a period of 1-2 weeks, up to six weeks in some patients, see Figure 1 . 4, 19 Necrotic skin lesions can be seen in immunocompromised or elderly patients. Lesions may resolve rapidly and completely, or may lead to a chronic course and linger for years.
As with chickenpox, once crusting occurs, the lesions cease to be infectious. Scarring with hypopigmentation or hyperpigmentation may persist over a long period.
Ocular Manifestations
Ocular manifestations affect about 50 % of patients with HZO and can be isolated. This proportion reaches 80 % in case of appearance of the Hutchinson Sign. This latter reflects the involvement the naso-ciliary branch and is characterized by eruption on the side and the tip of the nose.
20-22
Cornea Varicella zoster virus related stromal keratitis are quite similar to those related to HSV1 (see Figure 2 ) except that they show a higher tendency toward intense inflammation with major corneal neovascularization and subsequent lipidic keratopathy. 23 All these manifestations may be the consequence of a variable immune reaction to residual viral production and should be treated with inflammation-adjusted corticosteroid therapy and antiviral drugs.
1,19
Serpiginous keratitis is a rare but dreadful form of Varicella zoster virus related corneal complication that presents as a peripheral ulcerative keratitis with infiltration and thinning, adjacent to a zone of limbal vasculitis. it may progress to neovascularization or perforation. 19 Treatment is challenging and should be tailored to the risk of perforation.
it incudes local or systemic corticosteroids, systemic antiviral therapy, autologous serum eyedrops and conservative surgical procedures such as amniotic membrane grafting. 23 Corneal muquous plaques are another rare but classic HZO complication. 30, 31 This epithelial keratopathy occurs several months after the eruptive stage and is characterized by muquous plaques of variable size and location, migratory in nature. it is frequently associated Section Heading Section sub TOUCHOPHTHALMOLOgy with peripheral interstitial keratitis and/or chronic anterior uveitis. 1, 19 Pathogenesis is unclear: chronic epitheliopathy should be caused by either a low grade viral replication, immune reactions or neurotrophic mechanisms. 32 Treatment should include lubricant eyedrops and antiviral therapy. Anti-inflammatory eyedrops should be use cautiously because of the risk of persistant epithelial defects.
1,19,32
Neurotrophic keratopathy is a frequent complication of HZO. it results from the axonal loss in neurones where VZV replicates (see Figure 3 ).
Corneal hypoesthesia is the landmark of neurotrophic keratopathy and appear in average three days after the onset of the rash. 33 it is accompanied by perturbations of epithelial cicatrization, leading to corneal abnormality ranging from punctate superficial keratitis to persistent epithelial defects with vascularization and perforation. 34 A stepwise treatment should be considered, beginning with eviction of all potential epithelial toxicity: antiviral and preservative-containing should be withdrawn. Conversely, lubricant eyedrops are necessary to wash out all the inflammatory mediators staying at the ocular surface.
if the ulceration still progresses, instillation of autologous serum eye drops or amniotic membrane graft can be used to promote healing. 35 Finally, corneal perforations may be treated with cyanoacrylate tissue adhesive if small, whereas larger perforations may require surgical correction with either multilayered inlay grafting of amniotic membrane or full thickness corneal patch graft. 23, [36] [37] [38] Conjonctiva, Episclera, Sclera Figure 4) , a feature that is often useful for the retrospective diagnosis of a VZV (or HSV) related episode of intraocular inflammation.
12,43
VZV necrotizing retinitis is a rare but disastrous complication. it occurs either quickly after the eruptive stage or in a delayed fashion and can arise in patients without any cutaneous signs (zoster sine herpete) 15 it is more frequent and severe in immunocompromised patients.
Eyelids
While eyelid swelling with ptosis is common during the acute eruptive stage, cicatricial changes caused by dermal retraction are more prone to cause ectropion, entropion, ectopic lashes leading to corneal irritation and/or exposure keratopathy 19, 23, 24 , which is more pejorative when corneal sensitivity is also impaired. 1 Lagophthalmos may also results from associated facial nerve palsy. Numerous surgical techniques have been described to improve eyelid disorders and prevent corneal perforation. 23 
Neuro-ophthalmologic Manifestations
Oculomotor nerve palsies may occur after herpes zoster ophthalmicus. The third cranial nerve is the most commonly affected but other presentations including multiple and combined oculomotor nerve palsies can be seen.
44,45
Optic neuritis can be isolated or be associated with necrotizing retinitis or other neurological signs.
19,46
Post Herpetic Neuralgia
Post herpetic neuralgia (PHN) is the most common and one of the most dreadful complications of herpes zoster. it is defined as pain persisting beyond one month after rash onset or rash resolution. 47, 48 Pain is located in the dermatome affected by the rash. Symptoms range from allodynia (hypersensitivity to superficial stimuli) and spontaneous sensations of electric shock, stinging, itching, and burning to deep intermittent lancinating or sharp pain. Post herpetic neuralgia deeply impacts the quality of life of patients affected and may cause suicide in elderly people. 48 The risk of PHN increases with i) the age of the patient, ii) the extension and the severity of the rash, iii) the presence of early neuralgia and the decline in corneal and cutaneous sensation.
4,49-51
The prevalence of PHN decreases with time, from 30 % at six weeks to 9 % at one year of HZO rash. 52 Pathogenesis of PHN is not completely elucidated but it may result from chronic inflammation persisting in the trigeminal pathways after the acute infection has resolved. Some studies even demonstrated granulomatous arteritis and lymphocytic infiltration around the trigeminal tract and in the mesencephalic nucleus months and even years after the clinical manifestations of herpes zoster ophthalmicus. 48, 53 This chronic inflammation may be associated with a low grade viral replication.
53,54
Figure 2: Stromal Keratitis Following Herpes Zoster Ophthalmicus (HZO)
Treatment of Herpes Zoster Ophthalmicus
The main objectives of HZO treatment are lowering the viral replication, accelerating healing, limiting severity and duration of pain and reducing the complications.
Antiviral Drugs: Mechanisms and Practical Use
Acyclovir (ACV) is the first antiviral drug which showed efficacy against VZV in randomized controlled clinical trials. it is a synthetic guanosine analogue which activation requires three phosphorylations. Once activated, it becomes a potent inhibitor of the viral DNA polymerase, a key enzyme for VZV replication.
47,55
The first phosphorylation is mainly achieved by the viral thymidine kinase (TK), expressed in productively infected cells, thus conferring its selectivity to acyclovir. Nevertheless, acyclovir may also be activated to a lesser extent by cellular kinases, inducing toxicity in rapidly renewing tissues such as corneal epithelium. However, this toxicity is much lower than that of first generation, directly active, antiviral drugs. For treatment of HZO, 800 mg of oral acyclovir should be prescribed five times daily (4 g per day), allowing plasmatic concentrations of 6,9 to 0,96 µmol/l, which are active on the majority of VZV strains. [56] [57] [58] [59] According to clinical study versus placebo, for 7-10 days of treatment with this dosage significantly reduces the risk of ocular complications such as dendritic keratitis at the acute phase and the delayed inflammatory eye disease such as stromal keratitis, uveitis, episcleritis and scleritis. [60] [61] [62] [63] [64] The treatment should be started as soon as the rash begins because any delay may increase the risk of ocular complications. 62, 65 Even if studies failed to demonstrate a benefit to treat patients for a longer period than seven days elderly patients, who are more prone to develop late complications, should benefit from a longer treatment.
2
Valacyclovir (VACV) is a prodrug of ACV obtained by valine esterification, that has a 3-5 times greater oral bioavailability than oral acyclovir. [66] [67] [68] Consequently, 1 g tid (3 g per day) of VACV is bio-equivalent to 800 mg five times a day (4 g per day) of Acyclovir. A multicentric randomized controlled trial has shown the clinical equivalence of VACV (3 g per day)
and ACV (4 g per day) in HZO. Furthermore, this therapeutic scheme improved patient's compliance. 69 Other studies indicate that VACV could be more efficient than ACV in preventing PHN for other locations of herpes zoster. 47, 70 Nevertheless, plasmatic concentrations obtained with 3 g per day of oral VACV do not surpass those obtained with 5 mg/k g/8 h of intravenous ACV. 66 As a result, the oral maximal dose of VACV should not be used instead of the classic 10 mg/kg/8h intraveinous ACV which is required for severe ocular complications of VZV infection (such as necrotizing retinitis) and/or in immunocompromised patients.
Famciclovir is another antiviral drug that can be use to treat herpes zoster. it is a prodrug form of penciclovir with improved oral bioavailability.
Like ACV, its phosphorylation requires a viral kinase. 47 As During the last fifteen years, the vaccination program has shown a 80 % decreased in hospitalizations and global costs related to varicella when compared to the nineties. 76 A vaccine against herpes zoster was approved by the US FDA in 2006
for the prevention of immunocompetent individuals over 60 years of age. it also uses the OKA strain, but 14 times more concentrated than the varicella vaccine. A randomized, placebo-controlled, multicenter trial, found that the vaccine reduced by 50 % the overall incidence of herpes zoster and the incidence of PHN by 66 %. 79 As for chickenpox, vaccinated patients who developed herpes zoster, had milder forms of the disease.
Paradoxically, models have projected that the incidence of zoster could rise over time as a result of childhood vaccination against varicella (due to the lack of boosting of immunity in adults through exposure to children with chickenpox), [81] [82] [83] although empirical data to date have failed to document such an effect. 84 Anyway, people vaccinated against varicella during their childhood, should benefit, at least partially, from a protection against herpes zoster.
Conclusion
in summary, HZO can cause visual loss and debilitating post herpetic neuralgia. Early diagnosis and prompt treatment reduce the rate and the severity of these complications. in difficult cases, a multidisciplinary approach including neurologists or pain specialist can be necessary.
Herpes zoster and varicella vaccination will change the epidemiologic features of this frequent and ubiquitous infection. n
